Education
About Us
Working with TipRanks
Follow Us
Aptorum Group Ltd (APM)
NASDAQ:APM
APM Stock Chart & Stats
$1.07
-$0.08(-4.69%)
At close: 4:00 PM EST
$1.07
-$0.08(-4.69%)
Day’s Range― - ―
52-Week Range$0.65 - $4.47
Previous CloseN/A
Volume172.64K
Average Volume (3M)113.32K
Market Cap
$6.88M
Enterprise Value$5.76M
Total Cash (Recent Filing)$874.24K
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding6,346,823
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-12.82
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.59
Enterprise Value/Ebitda-1.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.1
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Modest Leverage On Balance SheetRelatively low and improving leverage provides durable financial flexibility for a development-stage biotech. Lower debt service reduces near-term cash demands, enabling focus on R&D, partnerships, or M&A without immediate solvency pressure and supports strategic optionality over months.
Partnership/licensing-oriented Business ModelAgnostic go-to-market via licensing or selective commercialization suits a small clinical-stage biotech: it limits upfront commercial spend, leverages larger partners' distribution and regulatory capacity, and creates milestone/royalty upside that can sustainably fund R&D if candidates progress.
Strategic Merger And Diagnostics Validation ActivityAdvancing the DiamiR merger and ongoing validation collaborations (e.g., APOE testing) represent structural moves to add CLIA/CAP-certified diagnostics capability and scale. A successful integration could create durable revenue channels and accelerate commercialization of diagnostic services.
Bears Say
Zero Recent Revenue With Persistent Operating LossesEliminating product revenue while continuing to report losses is a long-term concern: without commercialized products or material licensing cash-ins, the company must rely on financing. That structural revenue shortfall increases execution and funding risk over the next several quarters.
Negative Operating Cash Flow And Ongoing BurnConsistent negative operating and free cash flow demonstrates the business cannot self-fund development. Persistent cash burn forces reliance on capital markets or partners, which can dilute shareholders, constrain program timelines, and limit sustained investment in clinical development.
Shrinking Assets And Equity Over TimeMaterial declines in assets and shareholders' equity reflect prolonged value erosion from operating losses. Reduced balance sheet reserves constrain the company's ability to fund trials, secure partnerships, or withstand setbacks, increasing structural financing pressure in the medium term.
Aptorum Group News
APM FAQ
What was Aptorum Group Ltd’s price range in the past 12 months?
Aptorum Group Ltd lowest stock price was $0.65 and its highest was $4.47 in the past 12 months.
What is Aptorum Group Ltd’s market cap?
Aptorum Group Ltd’s market cap is $6.88M.
When is Aptorum Group Ltd’s upcoming earnings report date?
Aptorum Group Ltd’s upcoming earnings report date is Apr 24, 2026 which is in 51 days.
How were Aptorum Group Ltd’s earnings last quarter?
Aptorum Group Ltd released its earnings results on Sep 16, 2025. The company reported -$0.062 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.062.
Is Aptorum Group Ltd overvalued?
According to Wall Street analysts Aptorum Group Ltd’s price is currently Overvalued.
Does Aptorum Group Ltd pay dividends?
Aptorum Group Ltd does not currently pay dividends.
What is Aptorum Group Ltd’s EPS estimate?
Aptorum Group Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptorum Group Ltd have?
Aptorum Group Ltd has 6,346,823 shares outstanding.
What happened to Aptorum Group Ltd’s price movement after its last earnings report?
Aptorum Group Ltd reported an EPS of -$0.062 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.612%.
Which hedge fund is a major shareholder of Aptorum Group Ltd?
Currently, no hedge funds are holding shares in APM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptorum Group Ltd
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---